Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes

Expert Review of Endocrinology and Metabolism

Volumn 5, Issue 4, 2010, Pages 495-505

  Hribal, Marta Letizia ^a   Sesti, Giorgio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

GLP 1; incretin mimetics; LEADTM program; liraglutide; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; ROSIGLITAZONE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG TOLERABILITY; GLUCAGON RELEASE; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; INSULIN RELEASE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; WEIGHT REDUCTION;

EID: 77954866657     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.10.20     Document Type: Review

References (59)

1. Crandall JP, Knowler WC, Kahn SE et al. The prevention of Type 2 diabetes. Nat. Clin. Pract. Endocrinol. Metab. 4(7), 382-393 (2008).
2. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustments of therapy.Diabetes Care 32, 193-203 (2009).
3. Ford ES, Li C, Little RR, Mokdad AH. Trends in Alc concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 31, 102-104 (2008).
4. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
5. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with Type 2 diabetes: a retrospective cohort study. Lancet 375(9713), 481-489 (2010).
6. Zannad F. Implications of the ADVANCE study for clinical practice. J. Hypertens. 26(3), S29-S32 (2008)
7. Kilpatrick ES, Rigby AS, Atkin SL. The Diabetes Control and Complications Trial: the gift that keeps giving. Nat. Rev. Endocrinol. 5(10), 537-545 (2009).
8. Weiss IA, Valiquette G, Schwarcz MD. Impact of glycemic treatment choices on cardiovascular complications in Type 2 diabetes. Cardiol. Rev. 17(4), 165-175 (2009).
9. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2424-2443 (2006).
10. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycemia in Type 2 diabetes. Diabet. Med. 25, 245-254 (2008).
11. Sesti G. Harnessing the weight-regulating properties of glucagon-like-peptide-1 in the treatment of Type 2 diabetes. Diabetes Obes. Metab. 11(S3), 4-10 (2009).
12. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with Type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes. Metab. 10(1), 25-32 (2008).
13. Hauber AB, Mohamed AF, Johnson FR et al. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet. Med. 26, 416-424 (2009).
14. Patel A, ADVANCE Collaborative Group, MacMahon S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840 (2007).
15. Ma J, Rayner CK, Jones KL, Horowitz M. Insulin secretion in healthy subjects and patients with Type 2 diabetes - role of the gastrointestinal tract. Best Pract. Res. Clin. Endocrinol. Metab. 23(4), 413-424 (2009).
16. H0jberg PV, Vilsboll T, Rab0l R et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose- dependent insulinotropic polypeptide in patients with Type 2 diabetes. Diabetologia 52(2), 199-207 (2009).
17. Vilsboll T. The effects of glucagon-like peptide-1 on the (b-cell. Diabetes Obes. Metab. 11(3), 11-18 (2009).
18. Vilsboll T, Holst JJ, Knop FK. The spectrum of antidiabetic actions of GLP-1 in patients with Type 2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 23(4), 453-462 (2009).
19. Deacon CF. What do we know about secretion and degradation of incretin hormones? Regul. Pept. 128, 117-124 (2005).
20. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in Type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24, 1416-1421(2001).
21. Bailey C. New therapies for diabesity. Curr. Diab. Rep. 9(5), 360-367 (2009).
22. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results. Best Pract. Res. Clin. Endocrinol. Metab. 23(4), 463-477 (2009).
23. Vilsboll T, Zdravkovic M, Lee-Thi T et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with Type 2 diabetes mellitus. Diabetes Care 30, 1608-1610 (2007).
24. Chang AM, Jakobsen G, Sturis J. The GLP-1 derivative NN2211 restores p-cell sensitivity to glucose in Type 2 diabetic patients after a single dose. Diabetes 52, 1786-1791 (2003).
25. Degn KB, Juhl CB, Sturis J et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative (NN2211) markedly improves 24-h glycemia and a and p-cell function and reduces endogenous glucose release in patients with Type 2 diabetes. Diabetes 53, 1187-1194 (2004).
26. Bregenholt S, Moldrup A, Blume N et al. The long-acting glucagon-like peptide-1 analog, liraglutide inhibits p-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330, 577-584 (2005).
27. Toso C, McCall M, Merani S et al. Liraglutide,a long-acting human glucagon- like peptide 1 analogue, improves human islet survival in culture. Transpl. Int. 23(3), 259-265 (2009).
28. Vilsboll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet. Med. 25(2), 152-156 (2008).
29. Juhl CB, Hollingdal M, Sturis J et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in Type 2 diabetes. Diabetes 51, 424-429 (2002).
30. Horowitz M, Flint A, Doran S et al. Effects of the once-daily human GLP-1 analog liraglutide on appetite and energy intake in Type 2 diabetes. Diabetologia 51, S355 (2008).
31. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in Type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32(1), 84-90 (2009).
32. Zinman B, Jerich J, Buse JB et al. Efficacy and safety of the glucagon-like peptide 1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 MET+TZD) Diabetes Care 32, 1224-1230 (2009).
33. Buse JB, Rosenstock J, Sesti G. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomized, parallel-group, multi-national, open-label trial (LEAD-6). Lancet 374, 39-47 (2009).
34. Astrup A, Rossner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 374, 1606-1616 (2009).
35. Raun K, Von-Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon- like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity 15, 1710-1716 (2007).
36. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet 373, 473-481 (2008).
37. Jendle J, Nauck MA, Matthews DR et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for Type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes. Metab. 11(12), 1163-1172 (2009).
38. Courreges JP, Vilsboll T, Zdravkovic M et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med. 25(9), 1129-1131 (2008).
39. Noyan-Ashraf MH, Momen MA, Ban Ket al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975-983 (2009).
40. Fonseca V, Madsbad S, Falahati A, Zychma MJ, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic BP - a meta-analysis of 6 clinical trials. 545-P 69th Scientific Session American Diabetes Association. LA, USA, 5-9 June 2009.
41. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol. 201(1), 59-66 (2009).
42. Bjornsdottir I, Olsen A, Larsen U et al. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Diabetologia 51, S356 (2008).
43. Elbrond B, Jakobsen G, Larsen S et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single dose NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25, 1398-1404 (2002).
44. Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyam S. Tolerability, pharmacokinetics, and pharmacodynamics of the once-daily human GLP-1 analogue liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo- controlled dose-escalation study. Int. J. Clin. Pharmacol. Ther. 46, 273-279 (2008).
45. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily human glucagon-like peptide 1 analogue liraglutide. J. Clin. Pharmacol. 46, 635-641 (2006).
46. Kapitza C, Flint A, Spitzer H, Hindsberger C, Zdravkovic M. The effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. Diabetes 57, A593 (2008).
47. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol. 68(6), 898-905 (2009).
48. Flint A, Nazzal K, Jagielski P, Segel S, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide Diabetes 56, A145 (2007).
49. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycaemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 27, 1335-1342 (2004).
50. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose- Response Study Group. Effects of liraglutide (NN2211), a long-acting glucagon-like peptide 1 analog, on glycemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med. 22(8), 1016-1023 (2005).
51. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and body weight in subjects with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 114(8), 417-423 (2006).
52. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 analog, on glycemic control and body composition and 24-h energy expenditure in patients with Type 2 diabetes. Diabetes Care 27(8), 1915-1921 (2004).
53. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with Type 2 diabetes. Diabetes Res. Clin. Pract. 81(2), 161-168 (2008).
54. Madsbad S. Liraglutide Effect and Action in Diabetes (LEADTM) trial. Expert Rev. Endocrinol. Metab. 4(2), 119-129 (2009).
55. Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 26(3), 268-278
56. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in Type 2 diabetes mellitus (LEAD-5 met+SU: a randomised controlled trial. Diabetologia 52(10), 2046-2055 (2009).
57. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with Type 2 diabetes. Curr. Med. Res. Opin. 26(5), 1013-1022
58. Kaku K, Rasmussen MF, Clauson P, Seinov Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with Type 2 diabetes. Diabetes Obes. Metab. 12(4), 341-347 (2010).
59. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of Type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33, 428-433 (2010).